KR20220077091A - 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제 - Google Patents

1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제 Download PDF

Info

Publication number
KR20220077091A
KR20220077091A KR1020210167928A KR20210167928A KR20220077091A KR 20220077091 A KR20220077091 A KR 20220077091A KR 1020210167928 A KR1020210167928 A KR 1020210167928A KR 20210167928 A KR20210167928 A KR 20210167928A KR 20220077091 A KR20220077091 A KR 20220077091A
Authority
KR
South Korea
Prior art keywords
api
formulation
weight
oral formulation
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020210167928A
Other languages
English (en)
Korean (ko)
Inventor
유석철
이선
윤덕일
박정홍
선현지
Original Assignee
주식회사 엘지화학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지화학 filed Critical 주식회사 엘지화학
Publication of KR20220077091A publication Critical patent/KR20220077091A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020210167928A 2020-12-01 2021-11-30 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제 Pending KR20220077091A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200166051 2020-12-01
KR20200166051 2020-12-01

Publications (1)

Publication Number Publication Date
KR20220077091A true KR20220077091A (ko) 2022-06-08

Family

ID=81854222

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210167928A Pending KR20220077091A (ko) 2020-12-01 2021-11-30 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제

Country Status (15)

Country Link
US (1) US20240000751A1 (https=)
EP (1) EP4257123A4 (https=)
JP (1) JP7678106B2 (https=)
KR (1) KR20220077091A (https=)
CN (1) CN116528852A (https=)
AR (1) AR124178A1 (https=)
AU (2) AU2021390901B9 (https=)
CA (1) CA3197405A1 (https=)
CL (1) CL2023001215A1 (https=)
CO (1) CO2023008265A2 (https=)
MX (1) MX2023005459A (https=)
PE (1) PE20240222A1 (https=)
TW (3) TWI896975B (https=)
WO (1) WO2022119269A1 (https=)
ZA (1) ZA202305156B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240242A1 (es) * 2021-06-15 2024-02-16 Lg Chemical Ltd Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101424013B1 (ko) 2011-04-06 2014-08-18 주식회사 엘지생명과학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법
KR101751325B1 (ko) 2009-10-07 2017-06-27 주식회사 엘지화학 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000862A (es) * 2002-07-31 2005-04-19 Pharmacia Corp Forma de dosificacion farmaceutica capaz de mantener un perfil de disolucion estable tras el almacenamiento.
DE602006014607D1 (de) * 2005-01-21 2010-07-15 Teva Pharma Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung
JP5330989B2 (ja) * 2007-04-11 2013-10-30 キッセイ薬品工業株式会社 （アザ）インドール誘導体及びその医薬用途
WO2020109319A1 (en) * 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide
US20240000750A1 (en) * 2020-11-04 2024-01-04 Lg Chem, Ltd. Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
PE20230850A1 (es) * 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
TWI903066B (zh) * 2021-04-16 2025-11-01 南韓商Ｌｇ化學股份有限公司 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101751325B1 (ko) 2009-10-07 2017-06-27 주식회사 엘지화학 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
KR101424013B1 (ko) 2011-04-06 2014-08-18 주식회사 엘지생명과학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법

Also Published As

Publication number Publication date
TWI896975B (zh) 2025-09-11
CL2023001215A1 (es) 2023-12-15
CA3197405A1 (en) 2022-06-09
WO2022119269A1 (ko) 2022-06-09
JP7678106B2 (ja) 2025-05-15
EP4257123A1 (en) 2023-10-11
AU2021390901B9 (en) 2024-11-21
AU2024227367A1 (en) 2024-10-31
JP2023551712A (ja) 2023-12-12
ZA202305156B (en) 2024-09-25
AU2021390901A1 (en) 2023-06-08
TW202600130A (zh) 2026-01-01
AU2021390901B2 (en) 2024-11-07
TW202408496A (zh) 2024-03-01
TWI840721B (zh) 2024-05-01
PE20240222A1 (es) 2024-02-16
AU2021390901A9 (en) 2024-05-23
US20240000751A1 (en) 2024-01-04
CN116528852A (zh) 2023-08-01
EP4257123A4 (en) 2024-05-08
AR124178A1 (es) 2023-02-22
CO2023008265A2 (es) 2023-06-30
TW202228679A (zh) 2022-08-01
MX2023005459A (es) 2023-05-23

Similar Documents

Publication Publication Date Title
AU778203B2 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2024227367A1 (en) Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
NO342977B1 (no) Racecadotriltablett, fremgangsmåte for fremstilling av slike og slike tabletter for behandling av diaré
WO2004054574A1 (ja) 経口固形医薬
WO2017208136A1 (en) Pharmaceutical composition of dapagliflozin co-crystal
KR102585644B1 (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제
KR100591142B1 (ko) 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
JP2025039725A (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む経口用製剤、およびその製造方法
KR102749903B1 (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제
HK40095726A (zh) 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂
JP7195354B2 (ja) 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤
KR20250000758A (ko) 리나글립틴 및 메트포르민을 포함하는 복합 정제
KR20240040407A (ko) 사쿠비트릴ㆍ발사르탄 칼슘염을 포함하는 약제학적 조성물
WO2023107082A1 (en) A film coated tablet of saxagliptin and at least one antioxidant processed with wet granulation
TR2022013349A2 (tr) Li̇nagli̇pti̇n i̇hti̇va eden farmasöti̇k kompozi̇syonlar
WO2012133918A1 (en) Solid preparation
HK1130181A (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20211130

PA0201 Request for examination
PG1501 Laying open of application
A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20230131

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

Patent event date: 20211130

Patent event code: PA03021R01I

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230920

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250624